Vironexis Biotherapeutics key facts
as of Oct 2026- Developer of a cancer treatment biotechnology designed to offer AAV-delivered T-cell Immunotherapy.
- Vironexis Biotherapeutics is valued at approximately $125.0M as of Oct 2026 (last reported valuation).
- It has raised $52.0M; the latest was Later Stage VC ($26.0M) in Mar 2026.
- Notable investors include Capital Factory, Drive Capital, Future Ventures (San Francisco), Rev1 Ventures, Moonshots Capital — 6 tracked in total.
- Status: Privately Held (backing).
Vironexis Biotherapeutics's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·Watch Vironexis Biotherapeutics: the Monday email on marks, rounds and moves
Vironexis Biotherapeutics funding rounds
No funding rounds for Vironexis Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Vironexis Biotherapeutics
6Vironexis Biotherapeutics valuation
Vironexis Biotherapeutics's last reported valuation was $125 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Vironexis Biotherapeutics investors
6 investors are on record for Vironexis Biotherapeutics, including Capital Factory, Drive Capital, Future Ventures (San Francisco) and Rev1 Ventures.
About Vironexis Biotherapeutics
Developer of a cancer treatment biotechnology designed to offer AAV-delivered T-cell Immunotherapy. The company's gene therapy technology enables the creation of off-the-shelf, single-dose gene therapies, enabling healthcare professionals to help cancer patients achieve better outcomes through T-cell-mediated cancer killing.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2021
- Employees
- 12
- Website
- vironexis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.